Brief: Alphamab Oncology Says Unit & Suzhou Alphamab Enter Technology Development Agreement
31/03/2020 15:12
March 31 (Reuters) - Alphamab Oncology 9966.HK :
* UNIT & SUZHOU ALPHAMAB ENTER TECHNOLOGY DEVELOPMENT
AGREEMENT
FOR OPTIMIZATION & TRANSFER OF PROCESSES FOR 3 DRUG CANDIDATES
OF CO
* UNIT & SUZHOU ALPHAMAB ENTERED TECHNOLOGY DEVELOPMENT
AGREEMENT
FOR PROCESS SCALE-UP RESEARCH OF KN052, A DRUG CANDIDATE OF CO
Source text for Eikon: urn:newsml:reuters.com:*:nHKS9WMZPm
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)